XNAS
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -1.12 | -0.85 | +24.11% | $463,000 | ✅ Beat | +0.06% | -4.53% | — |
| 2026-03-09 | Q4 2025 | -1.01 | -1.43 | -41.58% | $284,000 | ❌ Miss | +7.36% | -1.55% | +10.41% |
| 2025-11-05 |
| Q3 2025 |
| -0.88 |
| -0.97 |
| -10.23% |
| $396,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-03-11 | Q4 2024 | -0.85 | -0.81 | +4.71% | $1.3M | ✅ Beat | -6.33% | -11.29% | -33.28% |
| 2024-11-07 | Q3 2024 | -0.61 | -0.74 | -21.31% | $2.2M | ❌ Miss | -2.81% | -14.75% | -18.86% |
| 2024-03-21 | Q4 2023 | -1.01 | -0.71 | +29.70% | $457,000 | ✅ Beat | — | — | — |
Showing last 6 quarters.